secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001437749-24-015210
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Q1 net loss $16.6M; OLPRUVA launch with 4 patients, cash runway into 2026
-------------------------------------------------------------------------------

- Net loss of $16.6M ($0.40 loss per share) compared to $13.2M loss in Q1 2023.
- Revenue $3.4M, including $2.2M French arimoclomol EAP reimbursement and $1.2M AZSTARYS royalties.
- OLPRUVA commercial launch: 4 patient enrollments, ~75% covered lives as of May 1, 2024.
- Arimoclomol NDA PDUFA date set for September 21, 2024; KP1077 positive Phase 2 IH data.
- Debt refinancing with up to $100M; $60M drawn, net $14M added to cash; runway extends into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924015210/0001437749-24-015210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924015210/zvra20240403_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-015210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer